Fig A1.

(A) Results of next-generation sequencing of circulating tumor DNA (ctDNA) by Guardant360 for patient 1, day 402 (progression on nazartinib). The mutant allele fractions (percent cfDNA) are shown for each mutation detected. (B) Integrated Genomics Viewer figure demonstrating that T790M and C797S are coexistent on the same allele (cis configuration). (C) Results of subsequent ctDNA analysis on day 555 (progression on carboplatin/pemetrexed) with an overall increase in the mutant allele fraction of EGFR del19 and T790, whereas EGFR C797S declined slightly. (‡) Synonymous variant.